Oncimmune Regulatory News (ONC)

13 December 2018

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune appoints new Scientific Board

- Professor Peter W.M Johnson appointed as Chairman of Scientific Board comprising leading cancer experts

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces the appointment of a new Scientific Board (SB). Chaired by Professor Peter W.M Johnson, the SB includes Dr. Richard M Roope, Dr. Nora Pashayan and Professor Ola S Winqvist. The new SB members replace the previous members who have ably supported the Company through its first phase of growth, and reflects the Company's progress to focus on delivering personalised immunodiagnostics for the screening, detection and care of cancer.

Professor Peter W.M Johnson CBE MD FRCP FMedSci, an expert in the development and assessment of Immuno-Oncology, is Professor of Medical Oncology in Southampton, CRUK's Chief Clinician and Director of the Francis Crick Institute Cancer Research Network. Professor Johnson trained in Medical Oncology at St. Bartholomew's Hospital in London, where his research developed molecular techniques to detect very low levels of lymphoma in blood. Professor Johnson was awarded a CBE in the HM Queen Elizabeth II's 90th birthday honours list for services to medical research.

In addition to the appointment of Professor Johnson, the following have also been appointed to the SB:

Dr. Richard M Roope MA FRCGP is a General Practitioner and UK Clinical Lead for Cancer at the Royal College of General Practitioners. He is a Senior Clinical Advisor (Prevention and Early Diagnosis)​ at Cancer Research UK, and a member of the National Cancer Advisory Group. Dr. Roope trained at Cambridge University and the University of London graduating in 1987 with a Bachelor of Medicine and Surgery degree. In 2015, he was elected to Fellowship of the RCGP for contributions to Cancer Management.

Dr. Nora Pashayan MD MSc MSt PhD FFPH is a Clinical Reader in Applied Health Research at University College London, a qualified GP and Honorary Consultant in Public Health at University College London Hospitals, as well as a member of the Breast Cancer Now Scientific Advisory Board. She received a MSc in Epidemiology from London School of Hygiene and Tropical Medicine and MSt in Public Health and PhD from the University of Cambridge before commencing a research career at the University of Cambridge, focusing on early detection, particularly in risk-stratified screening of cancer.

Professor Ola S Winqvist MD PhD is a Professor of Cellular Immunotherapy at the Karolinska Institute and Senior Consultant in Clinical Immunology at the Karolinska University Hospital. Professor Winqvist received his medical qualification in 1991 at the University of Uppsala. He then went on to achieve a PhD, focusing on experimental medicine and autoantigens in Addison's disease. He held a post-doctoral position at the Scripps Research Institute in California for three years and was Chairman of the Swedish Clinical Immunology Society until 2017.

Dr Adam Hill, CEO of Oncimmune commented: "Oncimmune's forward strategy is designed to unlock the latent potential in the Company's immunogenic protein platform, through developing a number of commercial propositions, underpinned by leading immunodiagnostic science. I am delighted that Professor Johnson, preeminent as an authority in cancer and immunology, has accepted our offer to Chair the Company's new SB, leading a team of experts, namely Dr Roope, Dr Pashayan and Prof Winqvist, who are all leaders in their chosen fields at the intersection of Cancer and Immunology, as well as medical practitioners. I look forward to working with them, leveraging their expertise as we deliver the next chapter of Oncimmune's growth over the next three years.

"I would like to take this opportunity to thank Oncimmune's inaugural Scientific Advisory Board for their service and valuable contributions over the last three years; their support has proved invaluable and I wish them well in their future endeavours".

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5708

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT®-Lung and EarlyCDT®-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT®-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit www.oncimmune.com